| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0008-6363(97)00184-3 |
| P698 | PubMed publication ID | 9534862 |
| P2093 | author name string | R S Schwartz | |
| D R Holmes | |||
| L A Fitzpatrick | |||
| S A Mousa | |||
| T M Reilly | |||
| P W Tsao | |||
| S S Srivatsa | |||
| P2860 | cites work | Integrins: versatility, modulation, and signaling in cell adhesion | Q27860844 |
| A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators | Q28245573 | ||
| Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors | Q28645681 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
| Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques | Q33904134 | ||
| The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro | Q34201497 | ||
| Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor | Q34346157 | ||
| Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain | Q34442820 | ||
| A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex | Q34541247 | ||
| Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin | Q35764323 | ||
| Role of the alpha v beta 3 integrin in human melanoma cell invasion | Q36847392 | ||
| Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". | Q37358508 | ||
| Molecular and cellular biology of osteopontin Potential role in cardiovascular disease | Q37828199 | ||
| Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery | Q39869620 | ||
| What's potentially more effective than a Roto-Rooter and less toxic than Drano? Anti-adhesion mimetics! | Q40343856 | ||
| Integrins as dynamic regulators of vascular function | Q40392606 | ||
| The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells | Q41426562 | ||
| Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix | Q42454200 | ||
| Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin | Q42491831 | ||
| ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1 | Q44135907 | ||
| Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet‐derived growth factor‐BB | Q44143496 | ||
| The restenosis paradigm revisited: an alternative proposal for cellular mechanisms | Q46465948 | ||
| A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis | Q51152098 | ||
| Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months | Q56945638 | ||
| Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation | Q58481514 | ||
| Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model | Q67733219 | ||
| Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries | Q68432695 | ||
| Adventitial remodeling after coronary arterial injury | Q70866681 | ||
| The ligand recognition specificity of beta3 integrins | Q71070336 | ||
| Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: insights from a porcine coronary (re)stenosis model | Q71129379 | ||
| Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA | Q71608650 | ||
| Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro | Q71730176 | ||
| Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries | Q71792495 | ||
| Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro | Q72737106 | ||
| P433 | issue | 3 | |
| P921 | main subject | stenosis | Q2343082 |
| P304 | page(s) | 408-428 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Cardiovascular Research | Q4642329 |
| P1476 | title | Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation | |
| P478 | volume | 36 |
| Q37609369 | A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs |
| Q73422924 | Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction |
| Q37378757 | Activation of the integrins alpha 5beta 1 and alpha v beta 3 and focal adhesion kinase (FAK) during arteriogenesis |
| Q40436803 | Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species |
| Q35753055 | Analysis of in situ and ex vivo αVβ3 integrin expression during experimental carotid atherogenesis |
| Q37221177 | Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model |
| Q34754695 | Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications |
| Q30489686 | Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. |
| Q35549067 | Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity |
| Q55076224 | Comparing the Differential Diagnostic Values of 18F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients. |
| Q45864360 | DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection |
| Q42831038 | Darwin and the survival of the fittest in modern interventional cardiology. |
| Q33752896 | Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. |
| Q43692919 | Effect of cAMP on the function of endothelial cells and fibromuscular proliferation after the injury of the carotid and coronary arteries in a porcine model |
| Q52973694 | Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells. |
| Q33238884 | Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio. |
| Q44558883 | Effects of insulin-like growth factor-I on cultured human coronary artery smooth muscle cells |
| Q45044627 | Evaluation of endothelial cell integrins after in \ vitro contact with polyethylene terephthalate |
| Q28053441 | Fibronectin is an important regulator of flow-induced vascular remodeling |
| Q33994755 | Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). |
| Q45870761 | Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions. |
| Q35925211 | Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia |
| Q56944701 | Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention |
| Q34155355 | Loss of beta1-integrin enhances TGF-beta1-induced collagen expression in epithelial cells via increased alphavbeta3-integrin and Rac1 activity |
| Q28584210 | MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides |
| Q43003855 | One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial |
| Q30436731 | Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway |
| Q37344022 | Plasminogen activator inhibitor-1 regulates integrin alphavbeta3 expression and autocrine transforming growth factor beta signaling |
| Q33902104 | Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor |
| Q74404156 | Role of D and E domains in the migration of vascular smooth muscle cells into fibrin gels |
| Q30819009 | Snake venom disintegrin, saxatilin, inhibits platelet aggregation, human umbilical vein endothelial cell proliferation, and smooth muscle cell migration |
| Q43869017 | Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists |
| Q43981477 | Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists |
| Q60922525 | TGFβ, smooth muscle cells and coronary artery disease: a review |
| Q33912018 | Target molecules for anti-angiogenic therapy: from basic research to clinical trials |
| Q39007117 | The integrin ligand c(RGDf(NMe)Nal) reduces neointimal hyperplasia in a polymer-free drug-eluting stent system |
| Q33890371 | The mechanisms of coronary restenosis: insights from experimental models |
| Q36496252 | The pathobiology of the vessel wall: implications for imaging |
| Q37832151 | Vascular smooth muscle cell motility: From migration to invasion |
| Q73538114 | [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes] |
Search more.